Increased grip strength with sodium–glucose cotransporter 2

Journal of Diabetes

Volumn 8, Issue 5, 2016, Pages 736-737

  Sano, Motoaki ^a   Meguro, Shu ^a   Kawai, Toshihide ^b   Suzuki, Yoshihiko ^c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

^c HDC Atlas Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; HEMOGLOBIN A1C; IPRAGLIFLOZIN; LUSEOGLIFLOZIN;

ADULT; BODY MASS; CARBOHYDRATE INTAKE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FAT MASS; FEMALE; GRIP STRENGTH; HEART DISEASE; HUMAN; JAPANESE (PEOPLE); LEAN TISSUE; LETTER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SARCOPENIA;

EID: 84983070170     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12402     Document Type: Letter

References (5)

1. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117–28.
2. Leong DP, Teo KK, Rangarajan S et al. Prognostic value of grip strength: Findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015; 386: 266–73.
3. Bolinder J, Ljunggren Ö, Johansson L et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014; 16: 159–69.
4. Pardo PS, Boriek AM. The physiological roles of Sirt1 in skeletal muscle. Aging. 2011; 3: 430–7.
5. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after SGLT2 inhibition. Diabetes Care. 2015; 38: 1730–5.